TY - JOUR
T1 - Double‐Blind Multiple‐Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine
AU - SHEIDLER, VIVIAN R.
AU - ETTINGER, DAVID S.
AU - DIASIO, ROBERT B.
AU - ENTERLINE, JOHN P.
AU - BROWN, MICHAEL D.
PY - 1984/4
Y1 - 1984/4
N2 - Abstract: Twenty cancer patients who received chemotherapy were entered into a double‐blind crossover design antiemetic study comparing 1 mg levonantradol, an investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2,6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia. 1984 American College of Clinical Pharmacology
AB - Abstract: Twenty cancer patients who received chemotherapy were entered into a double‐blind crossover design antiemetic study comparing 1 mg levonantradol, an investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2,6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia. 1984 American College of Clinical Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=0021142573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021142573&partnerID=8YFLogxK
U2 - 10.1002/j.1552-4604.1984.tb01824.x
DO - 10.1002/j.1552-4604.1984.tb01824.x
M3 - Article
C2 - 6373843
AN - SCOPUS:0021142573
SN - 0091-2700
VL - 24
SP - 155
EP - 159
JO - The Journal of Clinical Pharmacology
JF - The Journal of Clinical Pharmacology
IS - 4
ER -